Showing 4161-4170 of 23240 results for "".
Disease-Modifying Advances in ATTR-CM Management
https://reachmd.com/programs/heart-matters/disease-modifying-attr-cm-management/49063/Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
https://reachmd.com/programs/neurofrontiers/spinal-muscular-atrophy-reveals-hidden-kidney-impairment-risk/54641/How Biologic Insights Are Refining Severe Asthma Care
https://reachmd.com/programs/clinicians-roundtable/biologic-insights-severe-asthma-care/54218/Given that severe asthma management is entering a new era of biologically driven precision, Dr. Sally Wenzel joins us to discuss the complexity within Type 2 inflammation and the limitations of relying on a single biomarker assessment. She also differentiates childhood-onset allergic asthma from aduTackling Atopic Dermatitis in Difficult-to-Treat Areas
https://reachmd.com/programs/dermconsult/atopic-dermatitis-difficult-to-treat-areas/49017/Managing atopic dermatitis in sensitive areas like the face, neck, and hands poses both clinical and emotional challenges for patients. As treatment strategies evolve, balancing efficacy, safety, and quality of life becomes essential, particularly when navigating topical limitations and systemic optFace Value with Modern Aesthetics: 2025 EYECODE Protocol Update Part 3
https://reachmd.com/series/face-value/face-value-with-modern-aesthetics-2025-eyecode-protocol-update-part-3/54626/In the final episode of this 3-part series, Modern Aesthetics medical editor Dr. Saami Khalifian, board member Dr. Sheila Barbarino, and Dr. John Fezza wrap up their discussion on the 2025 EYECODE Protocol Update. This episode breaks down what injectors should do rather than sending their patient toExploring the Future of Psoriasis Treatment with Oral Agents
https://reachmd.com/programs/dermconsult/future-psoriasis-treatment-oral-agents/39685/Novel oral therapies are expanding the possibilities for personalized care in psoriasis, offering biologic-like efficacy with greater flexibility. Join Dr. Christopher Bunick as he discusses the evolving role of oral agents in the future of psoriasis treatment and the importance of real-world data iBeyond Anemia: Why Iron Matters in Every Stage of Chronic Kidney Disease
https://reachmd.com/programs/clinicians-roundtable/beyond-anemia-why-iron-matters-in-every-stage-of-chronic-kidney-disease/37221/Iron deficiency in chronic kidney disease (CKD) has traditionally been addressed only in the presence of anemia. But emerging evidence and updated guidelines now support assessing and treating iron deficiency in CKD—even when anemia is not present. Here to share the latest insights from the AmericanCadherin-6 in Focus: Existing Antibodies, Emerging Applications
https://reachmd.com/programs/living-rheum/cadherin-6-in-focus-existing-antibodies-emerging-applications/32796/While cadherin-6 may not yet shift clinical practice in rheumatoid arthritis, its role as a surface-expressed, actionable target opens the door to rapid therapeutic development—particularly with existing antibodies already in clinical trials for urologic cancers. Dr. Gary Firestein discussesManaging Genotype-Positive Patients in Hereditary ATTR-CM
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/managing-genotype-positive-patients-in-hereditary-attr-cm/39316/Hereditary transthyretin amyloid cardiomyopathy (ATTRv-CM) can pose unique challenges for clinicians, particularly when it comes to treating genotype-positive individuals without overt symptoms. That's why a recent study explored the clinical characteristics, progression, and outcomes of family membTransforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
https://reachmd.com/programs/neurofrontiers/program-name/36466/New advances in Alzheimer’s treatment are reshaping how clinicians manage disease progression. Anti-amyloid monoclonal antibodies don’t reverse or cure the disease, but they can slow progression by reducing amyloid buildup and indirectly decreasing toxic tau production. Dr. Marc Haut, Director of th